Richard A Johnson
Radiology at 101 Ter, Gainesville, FL

8236488, Aug 7, 2012

Nov 11, 2004

10/579173

Hitoshi Endou - Kanagawa, JP
Yoshikatsu Kanai - Tokyo, JP
Richard J. Johnson - Gainesville FL, US
Karen L. Price - Dyfed, GB

Human Cell Systems, Inc. - Tokyo

C12Q 1/62, C07K 14/47

435 4, 436 12, 514 157

It is intended to clarify a transportation system participating in the uric acid uptake in vascular smooth muscle cells (VSMCs) and provide a novel remedy, a preventive or a treating agent for vascular disorders, hypertension and renal disorders with the use of a drug participating in this transportation system. It is also intended to provide a novel screening system for a remedy, a preventive or a treating agent for vascular disorders, hypertension and renal disorders with the use of such a transportation system. Namely, a medicinal composition for healing, preventing or treating vascular disorders, hypertension and renal disorders which comprises a drug having an effect of inhibiting the uric acid uptake by a uric acid transporter URAT1 and a pharmaceutically acceptable carrier; and a method of screening a substance efficacious for healing, preventing or treating vascular disorders, hypertension and renal disorders which comprises using a cell line expressing URAT1 in the presence or absence of a test compound and assaying the uric acid uptake level, cell proliferation ability or the amount of a monocyte chemotactic factor produced by the cells.

2007016, Jul 19, 2007

Aug 2, 2006

11/497608

Christopher Lademacher - Evanston IL, US
Lin Zhao - Vernon Hills IL, US
Richard Johnson - Gainesville FL, US

A61K 31/53, A61K 31/426, A61K 31/4196, A61K 31/415

514246000, 514365000, 514383000, 514406000

The present invention relates to methods of treating subjects suffering from pre-hypertension or hypertension by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.

5755750, May 26, 1998

Nov 8, 1996

8/746355

Jeffery C. Petruska - Melrose FL
Richard D. Johnson - Gainesville FL

University of Florida - Gainesville FL

A61N 118

607 75

Activity in different fibers of a nerve in an animal can be selectively blocked by applying direct electric current between an anode and a cathode attached to the nerve. The anode has base of silver foil with a tough shaped portion which has a first curved region coated with silver/silver chloride for contacting the nerve. The cathode includes a silver foil base which also has a tough shaped portion with a second curved region coated with silver/silver chloride for contacting the nerve. The second region is at least six times greater in area than the first region, so that the density of current conducted between the cathode and the nerve is significantly less than the current density at the anode. A signal generator produces a direct current stimulation signal between positive and negative output terminals that are connected respectively to the anode and cathode.

2008031, Dec 25, 2008

Jun 21, 2005

11/570902

Richard J. Johnson - Gainesville FL, US

UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. - Gainsville FL

A61K 38/44, A61P 13/12

424 944

Disclosed herein are methods of preventing acute renal failure, ARF, as well as treating and accelerating the recovery of patients experiencing ARF. The inventors believe that an elevated serum uric acid, either occurring at baseline in the patient, or being brought about post-operatively is a major factor leading to ARF. Specifically exemplified are methods that involve administering to a patient at risk of experiencing ARF a composition comprising a uric acid lowering agent.

2012022, Aug 30, 2012

Feb 1, 2012

13/364313

Richard J. Johnson - Gainesville FL, US
Takahiko Nakagawa - Gainesville FL, US

A61K 31/519, A61P 13/02, A61K 31/426

5142621, 514365

Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl.

8557831, Oct 15, 2013

Jul 21, 2005

11/572270

Richard J. Johnson - Gainesville FL, US
Takahiko Nakagawa - Gainesville FL, US

University of Florida Research Foundation, Inc. - Gainesville FL

A01N 43/90

5142633

Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5. 2 to 5. 5 mg/dl.

2010012, May 13, 2010

May 31, 2006

11/995943

Richard J. Johnson - Gainesville FL, US
Takahiko Nakagawa - Gainesville FL, US

A61K 31/519, A61K 31/425

5142621, 514365

Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl.